Tremfya phase 3 data shows skin clearance rates were maintained at 5 years with 55.5% of patients achieving an IGA score of 0% and 53% achieving PASI 100 response in VOYAGE 2 trial.
Dermatology Times Staff
Advertisement
Articles by Dermatology Times Staff
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Drug Topics
1
How PBMs Legally Challenged Arkansas’ Pharmacy Ownership Law | NCPA 2025
2
General Awareness of PBM Practices Driving Optimism for Independent Pharmacies | NCPA 2025
3
COVID-19 Vaccination Benefits Patients With Systemic Lupus Erythematosus
4
FDA Releases Biosimilar Guidance Pushing to Streamline Development
5
